Statistics from Altmetric.com
Additional interventions to combat the HIV/AIDS epidemic are needed urgently. Prevention interventions using antiretroviral agents to prevent sexually acquired HIV are being studied in humans. Current evidence suggests that, by reducing viral load to undetectable level, combination antiretroviral therapy used to treat and extend the life of HIV-infected individuals may also reduce their infectivity thereby reducing the risk of transmission to their uninfected partners.1 In 2010, a topical antiretroviral-based vaginal microbicide, Tenofovir 1% gel, was shown to reduce HIV acquisition among South African women.2 The iPrEX study is the first multicentre double-blinded randomised trial evaluating the efficacy and safety of antiretroviral drugs used as oral pre-exposure prophylaxis (PrEP) to prevent HIV infections.
The study enrolled HIV-seronegative men and transgender who have sex with men (MTSM) from 11 sites worldwide. The study drug, Emtricitabine (FTC) and Tenofovir Disoproxil Fumarate (TDF) combined in a single daily tablet (Truvada), …
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.